ライフサイエンスコーパス: Germany

1 niversity Hospital Schleswig-Holstein (Kiel, Germany).

2 Departments of University Hospital Muenster (Germany).

3 dimensional speckle tracking (2DCPA; TomTec, Germany).

4 children (N = 96) across cultures (India and Germany).

5 er laser platform (Wavelight GmbH, Erlangen, Germany).

6 examined using the Oculus Pentacam (Wetzlar, Germany).

7 lis OCT (Heidelberg Engineering, Heidelberg, Germany).

8 RT3/RCM, Heidelberg Engineering, Heidelberg, Germany).

9 y [HRT]; Heidelberg Engineering, Heidelberg, Germany).

10 reen RT-PCR Kit 1.0 from altona Diagnostics (Germany).

11 nitinol stent (Sinus-XL, Optimed, Esslingen, Germany).

12 red with ELISA (Diacordon, Diagenics, Essen, Germany).

13 lis OCT (Heidelberg Engineering, Heidelberg, Germany).

14 keratometry (Pentacam, Oculus GmbH, Wetzlar, Germany).

15 Module; Heidelberg Engineering, Heidelberg, Germany).

16 om the reference loess sequence of Nussloch (Germany).

17 ) or AT Lisa tri 839MP (Carl Zeiss AG, Jena, Germany).

18 modium falciparum transmission in nonendemic Germany.

19 hthalmology at Goethe-University, Frankfurt, Germany.

20 Death data were not available for Germany.

21 ata from 66 neonatal intensive care units in Germany.

22 se 1 clinical trial at one centre in Munich, Germany.

23 les collected in 2015 in the Netherlands and Germany.

24 m November 30 to December 2, 2016 in Berlin, Germany.

25 University Hospital Regensburg, Germany.

26 Tertiary university hospital in Germany.

27 Ophthalmology, Goethe University, Frankfurt, Germany.

28 samples from a background site near Leipzig, Germany.

29 conducted at 16 tertiary medical centers in Germany.

30 and 5.9% (95% CI, 5.2% to 6.6%) in northeast Germany.

31 ctive age band of the population of Leipzig, Germany.

32 26 hospitals in the USA, Canada, the UK, and Germany.

33 r-initiated single-center trial in Hannover, Germany.

34 17.3% (95% CI, 16.5% to 18.1%) in northeast Germany.

35 ehensive analysis of every inpatient case in Germany.

36 and June 2015 from a university hospital in Germany.

37 (Oncorhynchus mykiss) aquaculture farming in Germany.

38 (controls) collected from a DILI Biobank in Germany.

39 dy at a rural mountaintop station in central Germany.

40 outcomes of high-risk surgical procedures in Germany.

41 niversity Erlangen-Nurnberg, Erlangen (FAU), Germany.

42 ed from 9 intensive care units (ICUs) across Germany.

43 uents and receiving streams at nine WWTPs in Germany.

44 f Gabon, Ghana, Ecuador, the Netherlands and Germany.

45 male earnings in the nursing labor market in Germany.

46 cal performance status, from 15 hospitals in Germany.

47 ohlenstein-Stadel (HST) cave in southwestern Germany.

48 s and Dr Hans Ludwig Geisenhofer Foundation, Germany.

49 ne-day workshop at ISMB/ECCB 2013 in Berlin, Germany.

50 alcoholic) treated at 10 medical centers in Germany.

51 17 hospitals in the USA, Canada, France, and Germany.

52 rovided by the Federal Statistical Office of Germany.

53 rch institutes and outpatient centers across Germany.

54 t of Epileptology, University Hospital Bonn, Germany.

55 has seen changes in diagnosis and therapy in Germany.

56 on in 1965 in Karl Decker's lab in Freiburg, Germany.

57 August 2013 and June 2014 at 4 hospitals in Germany.

58 Heidelberg University Hospital, Heidelberg, Germany.

59 nd social and ethnic backgrounds from across Germany.

60 of 2014 at an urban site in central Leipzig, Germany.

61 , in Nijmegen, the Netherlands, and Cologne, Germany.

62 ation at 11 centers in the United States and Germany.

63 3 level III neonatal intensive care units in Germany.

64 ary wastewater effluent from a major city in Germany.

65 reasing incidence of keratinocyte cancers in Germany.

66 ed in a neonatal tertiary referral center in Germany.

67 ient or outpatient rehabilitation centres in Germany.

68 ost commonly notified bacterial enteritis in Germany.

69 uthern and central Black Forest in southwest Germany.

70 rious animal sources for human infections in Germany.

71 teaching of such ethics to students in Nazi Germany.

72 healthy participants in Leipzig and Berlin, Germany.

73 niversity Hospital Schleswig-Holstein, Kiel, Germany.

74 United Kingdom, Italy, Sweden, Finland, and Germany.

75 nity hospitals, and specialist practices) in Germany.

76 m the Lech River valley in southern Bavaria, Germany.

77 51 nurses (10 in Brazil, 9 in England, 10 in Germany, 10 in Ireland and 12 nurses in Palestine).

78 sed trial, 102 hospitals (Australia [three], Germany [11], New Zealand [two], Switzerland [three], an

79 produced the most articles (16), followed by Germany (13 articles), and China (7 articles).

80 ith AP from 3 countries (United Kingdom, 22; Germany, 136; and The Netherlands 386) and 8487 control

81 ion Augsburg) F4 study conducted in southern Germany (2006-2008).

82 ases were obtained for Augsburg and Dresden (Germany), 2011-2012; Chernivtsi (Ukraine), 2013 to March

83 week base study at nine treatment centres in Germany; 27 patients were enrolled in the dose-escalatio

84 tates (blacks 4.0%), Switzerland (3.4%), and Germany (3.0%).

85 period versus 3.5 (1.5-6.9) for 2004-2010 in Germany; 3.8 (1.4-8.3) for 1997-2003 versus 2.2 (0.3-7.8

86 (P < 0.0001) in Finland (5.3; IQR: 3.9-6.9), Germany (4.3; IQR: 3.1-5.5), and Sweden (3.7; IQR: 2.8-4

87 periods of Hungary (6000-2900 bc, n = 100), Germany (5500-3000 bc, n = 42) and Spain (5500-2200 bc,

88 Charite-University Medicine Berlin, Berlin, Germany, 8 eyes (3.8%) of 210 consecutively performed DM

89 (BI 655066, Boehringer Ingelheim, Ingelheim, Germany), a humanised monoclonal antibody targeting the

90 ne, University Hospital of Munster, Munster, Germany, according to international standards.

91 ug tomography (Pentacam HR; Oculus, Wetzlar, Germany) after penetrating femtosecond laser-assisted ke

92 480 patients from seven study centers across Germany, aged 18 to 58, were prescreened; 518 were asses

93 A laboratory experiment conducted in Germany aimed to separate the effect of recalling violen

94 CT (Heidelberg Engineering GmbH, Heidelberg, Germany), along with IOP measurements and standard autom

95 Among 18,735 survivors of first MM in Germany and 7,560 in Sweden, overall 752 and 349 SPCs we

96 t organic and conventional beer samples from Germany and all over the world were analyzed by using th

97 study of hospitals and private practices in Germany and Austria encompassing 1961 adults with commun

98 States, Norway, and Canada, intermediate in Germany and Belgium, and lower in the Netherlands and En

99 s (France and Canada), Boehringer Ingelheim (Germany and Canada), Servier, GlaxoSmithKline, Novartis,

100 s (France and Canada), Boehringer Ingelheim (Germany and Canada), Servier, GlaxoSmithKline, Novartis,

101 we analyzed the NPHV prevalence in northern Germany and characterized the clinical course of infecti

102 r acute myeloid leukemia (AML; SIR = 4.9) in Germany and for kidney cancer (2.3), AML (2.3) and nervo

103 Netherlands and UK) to <0.3% (in Lithuania, Germany and Greece).

104 illator implantation at 3 implant centers in Germany and Hungary.

105 ss the United States, Canada, Australia, and Germany and including colorectal cancer cases (n=8634) a

106 his approach to selected regions in the USA, Germany and Iran to evaluate the current aquifer regime.

107 ) clinical practice was conducted in France, Germany and Spain.

108 (SPCs) in multiple myeloma (MM) survivors in Germany and Sweden to provide etiological understanding

109 the 214-million-year-old Proganochelys from Germany and Thailand, it retains marginal teeth and lack

110 rus spread to seals of the coastal waters of Germany and the Netherlands, causing the death of thousa

111 This open-label, single-arm trial, done in Germany and the UK, included patients with acute HCV gen

112 in Germany) and three validation cohorts (in Germany and the USA) of patients with acute GVHD who had

113 otope measurements resulted in two clusters: Germany and United States (the single Czech stock groupe

114 veloped in Western countries (United States, Germany) and appeals to individualist tendencies, which

115 n Norway; Crohn's disease 322 per 100 000 in Germany) and North America (ulcerative colitis 286 per 1

116 sured with the Pentacam HR (Oculus, Wetzlar, Germany) and the Cassini (i-Optics, The Hague, Netherlan

117 kHz laser system (Carl Zeiss Meditec, Jena, Germany) and the second group included eyes that underwe

118 analysis, we analysed a training cohort (in Germany) and three validation cohorts (in Germany and th

119 administrative district of Dresden (Saxony, Germany), and all locally archived data from phase 3 tri

120 niversity of Freiburg (Freiburg im Breisgau, Germany), and Brigham and Women's Hospital-Harvard Medic

121 m((R)) platform (Millipore Sigma, Darmstadt, Germany), and confocal images of an in vivo mouse diseas

122 ctralis, Heidelberg Engineering, Heidelberg, Germany), and OCTA using AngioVue technologies (Optovue

123 a (Spain), BAMSE (Sweden), LISAplus and MAS (Germany), and PIAMA-NHS (the Netherlands).

124 from an archaeological assemblage in Western Germany, and argue that the widely used (and relatively

125 The massacre sites of Talheim, Germany, and Asparn/Schletz, Austria, have long been the

126 rlands, USA, Canada, Switzerland, UK, Italy, Germany, and Australia who received a busulfan-based con

127 egative breast cancer at 86 sites in Sweden, Germany, and Austria between February 20, 2007, and Sept

128 nada, the United States, Argentina, Finland, Germany, and Israel, including 1019 infants with gestati

129 its of university and community hospitals in Germany, and it included 380 adult patients with severe

130 orts from Iceland, the Netherlands, Hungary, Germany, and Italy, and a final meta-analysis, including

131 occurred in 60 participants (3%) in Hamburg, Germany, and Kilifi, Kenya.

132 shallow STE on Spiekeroog Island, North Sea, Germany, and linked our findings to trace metal and nutr

133 ospital-centric in Belgium, Canada, England, Germany, and Norway than in the Netherlands or the Unite

134 a, and Washington) and 3 in Europe (Finland, Germany, and Sweden), were followed up for T1DM-related

135 0 and 2003 by 6 ethics committees in Canada, Germany, and Switzerland were screened.

136 rom rural areas in Austria, Finland, France, Germany, and Switzerland, for the first year of life, co

137 abetic foot clinics in France, Spain, Italy, Germany, and the UK.

138 bee species across three countries (Hungary, Germany, and the United Kingdom).

139 the United States, Norway, Denmark, Sweden, Germany, and the United Kingdom.

140 5 countries (China, Czech Republic, Denmark, Germany, and the United States).

141 l at 21 experienced valve centres in Canada, Germany, and the USA.

142 known solid cyanide factory: Czech Republic, Germany, and United States.

143 ctralis; Heidelberg Engineering, Heidelberg, Germany), AngioPlex (Cirrus 5000 HD-OCT; Carl Zeiss Medi

144 nducted at Heidelberg University Hospital in Germany (April 2014-February 2016) included 150 patients

145 n activities, while the selected aquifers in Germany are natural flow-dominated.

146 Moreover, Viking Age samples from Haithabu, Germany, are traced back to the North East Arctic Atlant

147 d outcome of patients from five hospitals in Germany, Austria, and Italy.

148 Diabetes Prospective Follow-up Initiative in Germany, Austria, and Luxembourg.

149 ogy in the UK, Netherlands, Belgium, France, Germany, Austria, Denmark, Australia, and New Zealand).

150 is, Heidelberg Engineering GmbH, Heidelberg, Germany) before (<21 days) and after (<50 days) TE.

151 g the Dynamic Vessel Analyzer (Imedos, Jena, Germany) before (baseline) and 1 week and 1 month after

152 n integral part of the medical curriculum in Germany between 1939 and 1945.

153 The use of TAVR increased markedly in Germany between 2007 and 2013; the concomitant reduction

154 were enrolled from 52 cancer care centers in Germany between February 1, 2009, and January 31, 2010,

155 nd from six non-MSBase centres in the UK and Germany between Nov 1, 2015, and June 30, 2016.

156 ge's hospital and Harburg hospital, Hamburg, Germany) between June 2012 and May 2015.

157 ersity of Cologne Medical Centre in Cologne, Germany, between January 1, 2010, and December 31, 2014.

158 pective claims data of infants from Bavaria, Germany, born between 2005 and 2007 (n = 295,420), conta

159 erly Sorin; London, UK) and Maquet (Rastatt, Germany) brand HCU production sites, and unrelated envir

160 University of Lubeck E40-2009 and E26-2010 (Germany); CNSA, INSERM, MiRe-DREES, and IRESP (France);

161 from London (UK; cohorts 1 and 2), Giessen (Germany; cohort 3), and Paris (France; cohort 4).

162 effluents from a chemical-industrial area in Germany, collected by the passive sampler Blue Rayon.

163 ruited from centres in Spain, Italy, France, Germany, Czech Republic, Netherlands, Canada, and the US

164 milial Breast and Ovarian Cancer in Cologne, Germany; data analysis, November 1 through December 31,

165 13 study centres in Canada, the Netherlands, Germany, Denmark, and the UK), we assessed the effect of

166 quantify some of these feedbacks in Berlin, Germany, during the heat wave in 2006.

167 e (Hungary and United Kingdom) and positive (Germany) effects during crop flowering.

168 The setting was 38 stroke units across Germany (February 1, 2012, to December 31, 2014).

169 the United States, and the others were from Germany, Finland, and Brazil, totaling 1,911 TMD cases a

170 d, the Netherlands, the USA, Taiwan, the UK, Germany, Finland, Australia, Sweden, and France), with b

171 between 2001 and 2005 who were recruited in Germany for a population-based study, the Mamma Carcinom

172 nt Alpha AMS (Retina Implant AG, Reutlingen, Germany) for partial restoration of vision in end-stage

173 R kit 1.0; altona Diagnostics GmbH, Hamburg, Germany) for venepuncture plasma samples tested in a Pub

174 CH) have been produced in Bitterfeld-Wolfen, Germany, for about 30 years until 1982.

175 12 European tertiary care centers (Austria, Germany, France, and Belgium).

176 at 92 hospitals in England, Scotland, Wales, Germany, France, and Sweden.

177 In the Europe-4 countries (Germany, France, Italy, and United Kingdom), there are a

178 se 3 study (DESSOLVE III) at 20 hospitals in Germany, France, Netherlands, and Poland.

179 rolled, phase 3 trial (METOP) at 16 sites in Germany, France, the Netherlands, and the UK.

180 rom participants of screening colonoscopy in Germany from 2005 through 2010 and frozen at -80 degrees

181 with a pancreatic surgery procedure code in Germany from 2009 to 2013 were identified from nationwid

182 older than 65 years in the United States and Germany from 2012.

183 Crohn's disease [CD]; 236 male), enrolled in Germany from August 2013 through April 2014 and followed

184 es and NAFLD at a tertiary medical center in Germany from June 2013 through March 2015.

185 n Afghanistan or after medical evacuation to Germany from November 1, 2008, through July 1, 2013.

186 y of 12 healthy, H pylori-negative adults in Germany from October 2008 through March 2010.

187 Participants were recruited in Germany from the general population via a large statutor

188 ersity Hospital of Schleswig-Holstein, Kiel, Germany, from January 1, 2005, through December 31, 2015

189 aluated using the Pentacam (Oculus, Wetzlar, Germany), Galilei (Ziemer, Biel, Switzerland), and Siriu

190 multicenter cohort of 9 treatment centers in Germany (GECCO).

191 hy (HRT; Heidelberg Engineering, Heidelberg, Germany) glaucoma probability score (GPS), the HRT Moorf

192 11 high-income countries (Denmark, Finland, Germany, Greece, Hungary, Ireland, Japan, South Korea, T

193 spitals in Austria, Belgium, Canada, France, Germany, Greece, Italy, and the USA.

194 ountries (Canada, Costa Rica, Egypt, France, Germany, Greece, Italy, New Zealand, and the USA) for bi

195 scanner (Somatom Force; Siemens, Forchheim, Germany [group 2]).

196 idopsis Research, held in 1965 in Gottingen, Germany, > 54 000 papers that mention Arabidopsis thalia

197 patients undergoing bariatric procedures in Germany have been prospectively registered in an online

198 dicine, Eberhard Karls University (Tubingen, Germany), healthy, malaria-naive adults were allocated t

199 ntries (Australia, Belgium, Canada, Denmark, Germany, Hungary, Israel, the Netherlands, New Zealand,

200 mic institutions, in Canada, Czech Republic, Germany, Hungary, Japan, Poland, and the USA.

201 ted from the Czech Republic, California, and Germany in 1994, 1997, and 2003, respectively.

202 dy at a rural mountaintop station in central Germany in August 2012.

203 Schmallenberg virus (SBV) was discovered in Germany in late 2011 and then spread rapidly to many Eur

204 nella spiralis had entered the food chain in Germany in March 2013.

205 a large population-based screening study in Germany.In this cross-sectional study, 15,950 participan

206 cases of hemolytic uremic syndrome (HUS) in Germany, including 90 children.

207 nomes of an Early and End Neolithic dog from Germany, including a sample associated with an early Eur

208 public of the Congo, Denmark, Egypt, France, Germany, India, Norway, and Thailand) recruited particip

209 A case study in Germany indicates that plague penetrated further into Eu

210 However, in 1939, Germany introduced mandatory lectures on ethics as part

211 x photoscreeners (PlusOptix GmbH, Nuremberg, Germany) is used in many vision screening programs.

212 Australia, Canada, Denmark, Finland, France, Germany, Israel, Italy, Japan, New Zealand, Norway, Swed

213 tries worldwide (Australia, Belgium, France, Germany, Israel, Italy, New Zealand, Portugal, South Kor

214 als or clinics in Australia, Canada, France, Germany, Israel, Italy, Spain, and the UK, to assess the

215 from 52 clinical centres in Canada, France, Germany, Israel, Italy, Spain, the UK, and the USA.

216 a, Belgium, Canada, Chile, Colombia, France, Germany, Israel, Netherlands, New Zealand, Norway, Spain

217 ital, and private cancer centres) in France, Germany, Italy, and USA.

218 Australia, Austria, Belgium, Canada, France, Germany, Italy, Japan, Lithuania, Mexico, Netherlands, P

219 tional 39 sites in 11 countries (Canada, UK, Germany, Italy, Japan, South Korea, Taiwan).

220 ance among the G7 countries (Canada, France, Germany, Italy, Japan, the United Kingdom, and the Unite

221 ry care centres in Denmark, Estonia, France, Germany, Italy, Latvia, Lithuania, Romania, South Africa

222 uromuscular care centres in Belgium, France, Germany, Italy, Netherlands, Poland, and the UK.

223 tients with autoimmune blistering disease in Germany, Italy, Singapore, Israel, and the Netherlands.

224 ean study sites in Austria, Belgium, France, Germany, Italy, Spain, and the UK.

225 centres in five European countries (Denmark, Germany, Italy, Switzerland, and the UK) and randomly as

226 Industrialized countries (USA, UK, Germany, Japan, Italy, France and Canada) were the most

227 m-enhanced (Magnevist; Bayer Pharma, Berlin, Germany) magnetic resonance (MR) imaging of the abdomen

228 (n = 5,240), Great Britain (n = 4,489), and Germany (n = 10,457) to resolve this open research quest

229 cohorts of elderly from the Netherlands and Germany (n = 13,044).

230 20,818; 52.1%), England (N = 97,099; 41.7%), Germany (N = 24,434; 38.3%), and Norway (N = 6636; 44.7%

231 five university hospitals in Austria (n=1), Germany (n=1), and the USA (n=3).

232 ained from retail shops in Belgium (n=8) and Germany (n=2).

233 ctralis (Heidelberg Engineering, Heidelberg, Germany) (n = 600) OCT devices.

234 nt cohorts, three of white European descent (Germany, n = 4,975; the Netherlands, n = 613; and Czech

235 These fossils were collected at two sites in Germany, Neumark-Nord and Weimar-Ehringsdorf, and likely

236 s morhua) specimens from excavation sites in Germany, Norway, and the United Kingdom.

237 pathways and limited upward job mobility in Germany, nurses tend to be more homogenous in their moti

238 iography (Heidelberg Spectralis, Heidelberg, Germany), OCT angiography, and OCT angiography with the

239 lled trial at 25 hospitals, in Canada (two), Germany (one), and the USA (23).

240 measured by Cirrus (Carl Zeiss, Oberkochen, Germany) optic coherence tomography (OCT).

241 ground (defined as place of birth outside of Germany or Austria), body mass index, and glycated hemog

242 LPI (Visulas 532s; Carl Zeiss Meditec, Jena, Germany) or medical therapy (Travoprost 0.004%; Alcon-Co

243 plex/Kcentra/Confidex; CSL Behring, Marburg, Germany) or plasma, with dosing based on international n

244 of MDS in Childhood (EWOG-MDS) conducted in Germany over a period of 15 years.

245 of men (<5.5 cm; range, 6% in Iceland-41% in Germany; P<0.01) and 12% of women with iAAA (<5 cm; rang

246 At the national level in Germany, perioperative mortality is higher than anticipa

247 nes) from 31 centres in the USA, Canada, UK, Germany, Poland, and Australia.

248 d patients from 31 hospital-based centres in Germany, Poland, and the USA in this prospective, multic

249 occur where sensitization is uncommon (e.g., Germany, Poland, France).

250 (AT LISA tri839MP; Carl Zeiss Meditec, Jena, Germany) pre-enrollment.

251 a grassland biodiversity experiment in Jena, Germany, provided the opportunity to assess flooding res

252 stem (RETIport; Roland Consult, Brandenburg, Germany); pupil diameter was measured with an eye tracke

253 ring study in Mecklenburg-Western Pomerania (Germany) reveal peak cU(aq) up to 75 mug L(-1) but low b

254 ystem is not as cost-effective as in some of Germany's neighbouring countries, which, given present e

255 lmology centers: Toronto, Canada; Frankfurt, Germany; Salzburg, Austria; and Leuven, Belgium.

256 The United States, Brazil, and Germany show evidence of higher prevalence of HCV in HCC

257 vention centres in Belgium, Brazil, Denmark, Germany, Singapore, Spain, Switzerland, and the Netherla

258 hase 3 study at 40 sites in Belgium, Canada, Germany, South Africa, Spain, and the USA.

259 bladder, or urethra at 16 sites in Finland, Germany, Spain, the UK, and the USA.

260 isk for type 1 diabetes followed in Finland, Germany, Sweden, and the U.S.

261 Australia, Belgium, Canada, Denmark, France, Germany, Sweden, and the UK).

262 HLA-genotyped newborns from Finland, Germany, Sweden, and the United States were enrolled in

263 r sites across Argentina, Australia, France, Germany, Sweden, and the USA.

264 for-service reimbursement system (Australia, Germany, Switzerland, and the United States), the propor

265 rs, and guests from North and South America, Germany, Switzerland, Netherlands, and France, the meeti

266 ent of Ophthalmology, University of Cologne, Germany, tertiary hospital, performing 500 corneal trans

267 ted States), the Heinz Nixdorf Recall study (Germany), the Multi-Ethnic Study of Atherosclerosis (Uni

268 oup, multicentre trial (11 sites in Finland, Germany, the Netherlands, and Sweden), with optional 12-

269 iac surgery-related patients in Switzerland, Germany, the Netherlands, and the UK, 218 M chimaera iso

270 multicentre trial done in Belgium, Denmark, Germany, the Netherlands, Sweden, the UK, and the USA.

271 In a multicentre phase 3 trial in Belgium, Germany, the Netherlands, Switzerland, France, Sweden, A

272 himaera infections diagnosed in Switzerland, Germany, the Netherlands, the UK, the USA, and Australia

273 led study at 35 hospitals in Canada, France, Germany, the UK, and the USA.

274 rs, and policy makers) from the Netherlands, Germany, the United Kingdom, Ireland, Hungary, and Denma

275 a from 3 case-control studies carried out in Germany: the Mammary Carcinoma Risk Factor Investigation

276 iopromide, Ultravist 300; Schering, Berlin, Germany) thoracic abdominopelvic CT.

277 om 4 statutory health insurance providers in Germany to identify children aged 3 to 17 years with new

278 e (Heidelberg Engineering, Inc., Heidelberg, Germany) to discriminate between healthy and early glauc

279 Symposium (October 16-18, 2014, in Marburg, Germany) to discuss recent developments in this field.

280 nd development of guidelines met in Potsdam, Germany, to determine the data that should be reported i

281 t microbiota using two cohorts from northern Germany totaling 1,812 individuals.

282 United States (US $18,500), intermediate in Germany (US $16,221) and Belgium (US $15,699), and lower

283 hesis ArtificialIris (HumanOptics, Erlangen, Germany) used in this study is a novel and innovative de

284 e length of time for this transition in 2016 Germany was 2.9 years.

285 service employees and hunters from southwest Germany was performed.

286 le 1:1 randomization of general practices in Germany was used.

287 , TomTec Imaging Systems, Unterschleissheim, Germany) was applied for fully automated EF and LS measu

288 artery stenting (CAS) on a national level in Germany were analyzed.

289 ers Rhine and Main in the Rhine-Main area in Germany were analyzed.

290 n-ponds rainbow trout aquaculture farming in Germany were investigated with a special focus on musty-

291 ns from 2012 to 2014 at 2 centers in Munich, Germany, were prospectively collected.

292 ce value of 4mg/kg of morphine set by BfR in Germany, whereas 25% of the samples did not comply with

293 double-blind study conducted in 24 centres (Germany), which selectively included CSU patients with a

294 n in Potsdam and other parts of Brandenburg, Germany, who had complete data on cigarette smoking, too

295 ed liver and plasma samples from patients in Germany with chronic pancreatitis, pancreatic intra-epit

296 ar overall survival of children diagnosed in Germany with heritable retinoblastoma between 1940 and 2

297 e beautiful Herrenhausen Palace in Hannover, Germany with the goal of broadening our understanding of

298 Ls (Lentis LS-502-1; Oculentis GmbH, Berlin, Germany) with a hydrophobic surface that were explanted

299 using Rescan 700 (Carl Zeiss Meditech, Jena, Germany) with epiretinal membrane (ERM) and internal ret

300 oftware (Heidelberg Engineering, Heidelberg, Germany), with suspected areas of atrophy confirmed by S